0000000000274656

AUTHOR

Braun M

showing 2 related works from this author

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

Clinical Outcome and Subjective Quality of Life after Photodynamic Therapy in Patients with Age-Related Macular Degeneration

2005

PURPOSE. Whereas the efficacy of photodynamic therapy (PDT) in preventing the progression of age-related macular degeneration (ARMD) is established, its effect on quality of life is under discussion. METHODS. All patientswho underwent PDT during 2000 and 2001 at the University Eye Hospital of Mainz were interviewed using a standardized 82-item questionnaire on quality of life and patient satisfaction in ophthalmologic patients. Information was assessed in terms of 82 questions; global scores ranging from 1.0 (optimum self-estimated quality of life) to 4.0 (worst) were derived. Cataract patients' scores were used to characterize the ARMD patients' subjective outcome; the latter were then rel…

Malemedicine.medical_specialtyPorphyrinsVisual acuitymedicine.medical_treatmentVisual AcuityPsychological interventionPhotodynamic therapyLogistic regressionMacular Degeneration03 medical and health sciences0302 clinical medicinePatient satisfactionQuality of lifeSurveys and QuestionnairesInternal medicineActivities of Daily LivingmedicineHumansIn patientAgedRetrospective StudiesAged 80 and overPhotosensitizing Agentsbusiness.industryVerteporfinGeneral MedicineMacular degenerationmedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyCross-Sectional StudiesTreatment OutcomePhotochemotherapyPatient SatisfactionQuality of Life030221 ophthalmology & optometryPhysical therapyFemalemedicine.symptombusiness030217 neurology & neurosurgeryEuropean Journal of Ophthalmology
researchProduct